The value of diagnostic&nbsp; <sup>131</sup> I scan in PTC patients with unexplained hyperthyroglobulinemia

HE Ziyan; SA Ri; QIU Xian; WANG Junyao; CHEN Libo

doi:10.19732/j.cnki.2096-6210.2022.05.007

您当前的位置：

首页 >

文章列表页 >

The value of diagnostic ¹³¹ I scan in PTC patients with unexplained hyperthyroglobulinemia

更新时间：2025-12-15

- The value of diagnostic ¹³¹ I scan in PTC patients with unexplained hyperthyroglobulinemia
- Vol. 31, Issue 5, Pages: 498-503(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2022.05.007
  CLC：
- Published Online：28 October 2022，
  
  Published：28 October 2022
- 稿件说明：
移动端阅览
何紫燕,萨日,邱娴,等. 诊断性¹³¹ I扫描在不明原因高甲状腺球蛋白血症PTC患者处置中的价值[J]. 肿瘤影像学, 2022, 31(5): 498-503 https://doi.

org/10.19732/j.cnki.2096-6210.2022.05.007
何紫燕,萨日,邱娴,等. 诊断性¹³¹ I扫描在不明原因高甲状腺球蛋白血症PTC患者处置中的价值[J]. 肿瘤影像学, 2022, 31(5): 498-503 https://doi. DOI： 10.19732/j.cnki.2096-6210.2022.05.007.

org/10.19732/j.cnki.2096-6210.2022.05.007 DOI：

摘要

目的：

探索诊断性

131

I扫描（diagnostic

131

I scan，Dx）在不明原因高甲状腺球蛋白（thyroglobulin，Tg）血症甲状腺乳头状癌（papillary carcinoma of the thyroid，PTC）全切术后患者临床处置中的潜在价值。

方法：

连续纳入2019年3月2022年2月收治的血清促甲状腺激素（thyroid stimulating hormone，TSH）抑制性Tg＞1 ng/mL且无残甲和残留/复发/转移病灶影像学证据的PTC患者。患者口服74 MBq

131

I后24 h行Dx，当平面显像诊断不明确时立即加行单光子发射计算机体层摄影（single photon emission computed tomography，SPECT）/计算机体层成像（computed tomography，CT）。根据Dx结果等信息明确

131

I治疗目的后即给予患者口服治疗剂量

131

I，3 d后行治疗后全身扫描（post-therapeutic whole-body scan，Rx）。

结果：

在共67例不明原因高Tg血症PTC患者中，Dx阳性患者有8例（11.9%），Dx与Rx的结果匹配度达97.0%，Dx阴性预测值为94.9%。Dx阳性患者中，6例为颈淋巴结转移瘤，2例为纵隔淋巴结转移瘤。在随访终点时表现为生化缓解、稳定及进展的比例分别为87.5%（7/8）、12.5%（1/8）及0.0%（0/8）。除去1例转靶向治疗患者，剩余58例Dx阴性患者在随访终点时表现为生化缓解、稳定及进展的比例分别占79.3%（46/58）、12.1%（7/58）及8.6%（5/58），两组患者生化疗效差异无统计学意义（

=0.542）。

结论：

在不明原因高Tg血症PTC患者中，Dx与Rx具有高度一致性。前者可通过检出或排除摄碘PTC病灶明确

131

I治疗目的并保证良好疗效。

Abstract

Objective:

To evaluate the potential role of diagnostic

131

I scan (Dx) in the ma

nagment of totally thyroidectomizedpapillary carcinoma of the thyroid (PTC) in patients with unexplained hyperthyroglobulinemia.

Methods:

Totally thyroidectomized PTC patients with suppressed thyroglobulin levels higher than 1 ng/mL and no radiographic evidence of thyroid remnant or percistent/recurrent/metastatic disease were consecutively enrolled from March 2019 to February 2022. A Dx of spot imaging of 10 min covering from cranial base to transverse septum was performed 24 h after an oral administration of

131

I (74 MBq). Single photon emission computed tomography (SPECT)/computed tomography (CT) was immediately added if planar imaging showed inconclusive findings (the localization of lesions accumulating

131

I was unclear or a malignant lesion could not be ruled out). A therapeutic activity of

131

I was prescribed immediately after the goal of treatment was clarified by Dx. Three days later

a planar post-therapeutic whole-body scan (Rx) was conducted with SPECT/CT fusion imaging when needed.

Results:

In total of 67 PTC patients with unexplained hyperthyroglobulinemia

8 (11.9%) of patients were identified with positive Dx

with a coincidence rate of 97.0% between Dx and Rx and a negative predictive value of 94.9%. In patients with Dx-postive

two and six were identified with mediastinal and cervical lymph node metastasis

repectively. Biochemical remssion

stablization and progression were 87.5% (7/8)

12.5% (1/8)

and 0.0% (0/8)

respectively. After the exclusion of one patient who switched to targeted therapy

biochemical remission

stabilization

and progression were achieved in 79.3% (46/58)

12.1% (7/58) and 8.6% (5/58) of 58 patients with negative Dx

respectively. No significant difference in biochemical response was found in the two groups (

=0.542).

Conclusion:

The findings of Dx is highly consistent with those of Rx in totally thyroidectomized PTC patients with unexplained hyperthyroglobulinemia. Radiodine

-avid focis were detected or excluded

which is helpful to clarify the purpose of treatment

warranting therapeutic response.

关键词

Keywords

references

Views

995

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical value of ¹⁸ F-FDG PET/CT in ¹³¹ I treatment of metastases of differentiated thyroid cancer

The correlation between clinical and ultrasound features of papillary carcinoma of the thyroid and central lymph node metastasis and BRAF V600E gene mutation

Prediction of central lymph node metastasis in papillary carcinoma of the thyroid by nomogram based on ultrasonographic features

Research progress on the correlation between molecular markers and ultrasound features in papillary carcinoma of the thyroid

Related Author

SHENG Shiwei

WANG Yang

LU Hankui

WU Xiaofang

ZHANG Miaomiao

ZHAO Ruolan

WANG Ying

CHEN Wenqin

Related Institution

No data

AI问答

⁰

The value of diagnostic 131 I scan in PTC patients with unexplained hyperthyroglobulinemia

DOI：10.19732/j.cnki.2096-6210.2022.05.007

摘要

Abstract

关键词

Keywords

references

The value of diagnostic ¹³¹ I scan in PTC patients with unexplained hyperthyroglobulinemia